

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Hematopoietic prostaglandin D ₂ (PGD ₂); hematopoietic prostaglandin D ₂ synthase (HPGDS)	<p>A study in cell culture identified a nicotinamide-based HPGDS inhibitor that could help treat inflammation. In mouse bone marrow-derived macrophages, the nicotinamide-based inhibitor produced reductions in proinflammatory PGD₂ levels that were comparable to those recorded in historical data for a HPGDS inhibitor. Next steps include evaluating the nicotinamide-based compound in rodent models of asthma.</p> <p>SciBX 3(30); doi:10.1038/scibx.2010.927 Published online Aug. 5, 2010</p>	<p>Patent application filed covering use in inflammatory disorders; available for licensing from the Institute for Molecular Bioscience at The University of Queensland</p> <p>Contact: Mark Smythe, The University of Queensland, Brisbane, Queensland, Australia e-mail: m.smythe@imb.uq.edu.au</p>	<p>Christ, A.N. <i>et al. J. Med. Chem.</i>; published online July 20, 2010; doi:10.1021/jm100194a</p> <p>Contact: Jack U. Flanagan, The University of Auckland, Grafton, Auckland, New Zealand e-mail: j.flanagan@auckland.ac.nz</p>